European Urology Open Science最新文献

{"title":"3 Obesity and kidney stones","authors":"Kørting K., Jensen L.S., Øbro L.F., Osther S.S., Andreassen K.H., Osther P.J.S.","doi":"10.1016/S2666-1683(25)00034-5","DOIUrl":"10.1016/S2666-1683(25)00034-5","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S2"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Evaluation of Morbidity and Predictors of Response to Imiquimod Treatment for Penile Intraepithelial Neoplasia","authors":"Ofir Avitan ,&nbsp;Laura Elst ,&nbsp;Manon Vreeburg ,&nbsp;Tynisha Rafael ,&nbsp;Katja Jordanova ,&nbsp;Niels Graafland ,&nbsp;Kees Hendricksen ,&nbsp;Bas W.G. van Rhijn ,&nbsp;Henk G. van der Poel ,&nbsp;Maarten Albersen ,&nbsp;Oscar Brouwer","doi":"10.1016/j.euros.2024.08.020","DOIUrl":"10.1016/j.euros.2024.08.020","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts. The primary objective of our study was to assess the response to IQ treatment, associated SEs, and potential predictors of response in the largest reported cohort to date.</div></div><div><h3>Methods</h3><div>We conducted a collaborative retrospective study involving patients diagnosed with PeIN and treated with IQ between 2010 and 2022 in two high-volume centers in the Netherlands and Belgium. Eligible patients had a confirmed diagnosis of PeIN and a minimum of 6-mo follow-up. Response to IQ was categorized as a complete response (CR), partial response, or no response. Descriptive statistics were generated and statistical tests included the Mann-Whitney U test for age and Fisher’s exact test for categorical variables.</div></div><div><h3>Key findings and limitations</h3><div>The study included a total of 44 patients, with a median age of 65.4 yr (interquartile range 56–72). Of these patients, 28 (64%) achieved a CR, while 14 (32%) had a partial response and two (4.5%) had no response. In the CR subgroup, the 3-yr recurrence rate was 25%. No significant correlation was found between response status and age, human papillomavirus status, history of penile cancer, or circumcision before treatment. Among the patients, 50% reported SEs, mainly local pain, irritation, and bleeding, and 12% discontinued treatment because of SEs. There was no significant correlation between CR and the incidence or type of SE.</div></div><div><h3>Conclusions and clinical implications</h3><div>Despite the high overall response rate to IQ, a significant number of patients experienced local recurrence within 3 yr, and approximately half of the patients reported SEs. Our results did not identify any clinical or pathological factors or local SEs predictive of the therapeutic response to IQ. Prospective studies are needed to help in predicting which patients are likely to respond to IQ so that those who will not benefit can be spared the SEs associated with this treatment.</div></div><div><h3>Patient summary</h3><div>Our study looked at responses to imiquimod (IQ), an immune-based treatment in cream format, for precancerous lesions on the penis, called penile intraepithelial neoplasia. More than 95% of patients had a complete or partial response to IQ, but 50% reported side effects, and 25% of the group with a complete response had recurrence within 3 years. More research is needed to help in selecting patients who will benefit the most from IQ treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 63-68"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1 SMART GRAFT: Surgeon’s expertise and Machine learning Automated biopsy Reading Towards improving GRaft Assessment For Transplant","authors":"Figueiredo A.J.,&nbsp;Silva E.M.C.T.,&nbsp;Rodrigues L.M.A.,&nbsp;Nunes P. T. C.,&nbsp;Marconi L.S.O.,&nbsp;Retroz E.A.C.,&nbsp;Eliseu M.N.C.,&nbsp;Jarimba R.L.S.,Marques M.J.G.,&nbsp;Leal A.R.G.C.,&nbsp;Santos L.S.,&nbsp;Romaozinho C.P.R.M.,&nbsp;Sousa V.M.L.,&nbsp;Parada B.A.C.","doi":"10.1016/S2666-1683(25)00012-6","DOIUrl":"10.1016/S2666-1683(25)00012-6","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S1"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"11 Does the percentage of Gleason 4 in targeted prostate biopsies predict the percentage of Gleason 4 at final pathology in prostatectomy specimen? Implications for active surveillance","authors":"Walz J.,&nbsp;Cavigla A.,&nbsp;Knipper S.,&nbsp;Branger N.,&nbsp;Brunelle S.,&nbsp;Gravis G.,&nbsp;Salem N.,&nbsp;Pignot G.","doi":"10.1016/S2666-1683(25)00014-X","DOIUrl":"10.1016/S2666-1683(25)00014-X","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S12"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"15 Proteome signatures in urinary extracellular vesicles enable prostate cancer detection","authors":"Bijnsdorp I.V.,&nbsp;Erozenci L.A.,&nbsp;Knol J.C.,&nbsp;Pham T.V.,&nbsp;Piersma S.R.,&nbsp;Verhaegh G.,&nbsp;Schalken J.A.,&nbsp;Jenster G.,&nbsp;van Royen M.E.,Martens-Uzunova E.,&nbsp;Van Moorselaar R.J.A.,&nbsp;Jimenez C.R.","doi":"10.1016/S2666-1683(25)00018-7","DOIUrl":"10.1016/S2666-1683(25)00018-7","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S17"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"26 The development of a novel, multi-dimensional tool for the assessment of sexual dysfunction following radical prostatectomy: The RPQ","authors":"Mulhall J.P.","doi":"10.1016/S2666-1683(25)00030-8","DOIUrl":"10.1016/S2666-1683(25)00030-8","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S30"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"23 Efficacy and safety of trans-obturator tape vs. urethral bulking in female stress urinary incontinence. A randomized controlled trial","authors":"Costantini E.,&nbsp;Illiano E.","doi":"10.1016/S2666-1683(25)00027-8","DOIUrl":"10.1016/S2666-1683(25)00027-8","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S26"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls","authors":"Reidun Sletten ,&nbsp;Marit Slaaen ,&nbsp;Line Merethe Oldervoll ,&nbsp;Håvard Kjesbu Skjellegrind ,&nbsp;Jūratė Šaltytė Benth ,&nbsp;Lennart Åstrøm ,&nbsp;Øyvind Kirkevold ,&nbsp;Sverre Bergh ,&nbsp;Bjørn Henning Grønberg ,&nbsp;Siri Rostoft ,&nbsp;Asta Bye ,&nbsp;Paul Jarle Mork ,&nbsp;Ola Berger Christiansen","doi":"10.1016/j.euros.2024.11.005","DOIUrl":"10.1016/j.euros.2024.11.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>Whether radical prostate cancer treatment affects long-term physical performance and physical activity in older men is not known. We aimed to compare physical performance and self-reported physical activity between relapse-free older prostate cancer survivors and population-based controls.</div></div><div><h3>Methods</h3><div>A single-centre, cross-sectional study including 109 men aged ≥70 yr receiving robotic-assisted radical prostatectomy (61.5%) or external beam radiotherapy (38.5%) between 2014 and 2018 was conducted. Population-based matched (age, gender, and education) controls (<em>n</em> = 327) were drawn from the Trøndelag Health Study. The primary (the Short Physical Performance Battery [SPPB] summary score) and secondary (gait speed, grip strength, one-legged balance, and the self-reported Physical Activity Index) outcomes were compared between survivors and controls by adjusted linear mixed models.</div></div><div><h3>Key findings and limitations</h3><div>The SPPB score, gait speed, and Physical Activity Index did not differ between survivors (mean age 78.3 yr, mean time since treatment 52.9 mo) and controls (mean age 78.2 yr). Survivors had slightly poorer grip strength (regression coefficient [RC] –5.81, <em>p</em> &lt; 0.001, 95% confidence interval [CI] –7.46; –4.17) and one-legged balance (RC –4.36, <em>p</em> &lt; 0.001, 95% CI –6.72; –2.00; adjusted models), but the clinical significance is uncertain. Small sample size and potential selection of the fittest survivors are limitations that may reduce the generalisability of our findings.</div></div><div><h3>Conclusions and clinical implications</h3><div>3 to 8 yr after radical prostate cancer treatment, older men’s overall physical performance and physical activity level were comparable with those of matched controls. This suggests that the treatment had little impact on functional status.</div></div><div><h3>Patient summary</h3><div>In this study, we investigated physical function in older men several years after they had undergone curatively intended treatment for prostate cancer in comparison with men in a general population of the same age and education. We found that physical function was similar, except slightly poorer grip strength and balance on one leg in men treated for prostate cancer. We conclude that the overall physical function was comparable with that of the general population and believe that this indicates that prostate cancer treatment was well tolerated despite older age.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 87-95"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial","authors":"Federica Sordelli ,&nbsp;Antonio Desai ,&nbsp;Filippo Dagnino ,&nbsp;Roberto Contieri ,&nbsp;Sofia Giuriolo ,&nbsp;Marco Paciotti ,&nbsp;Vittorio Fasulo ,&nbsp;Stefano Mancon ,&nbsp;Davide Maffei ,&nbsp;Pier Paolo Avolio ,&nbsp;Giorgio Da Rin ,&nbsp;Federica Maura ,&nbsp;Elena Vanni ,&nbsp;Davide Federico ,&nbsp;Piergiuseppe Colombo ,&nbsp;Giovanni Lughezzani ,&nbsp;Nicolò Maria Buffi ,&nbsp;Paolo Casale ,&nbsp;Alberto Saita ,&nbsp;Massiomo Lazzeri ,&nbsp;Antonio Voza","doi":"10.1016/j.euros.2024.09.001","DOIUrl":"10.1016/j.euros.2024.09.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bladder cancer (BC) represents a significant health care challenge and is frequently detected during evaluations for haematuria in emergency departments (EDs). Our aim was to evaluate the clinical performance and economic implications of the Xpert BC Detection (BCD) test for patients presenting to the ED with haematuria to address the pressing need for more efficient and accurate diagnostic tools in this setting.</div></div><div><h3>Methods</h3><div>We conducted a prospective single-centre observational study in the ED of a tertiary university hospital. Patients presenting with gross haematuria as the primary reason for their visit were enrolled. Urine samples collected in the ED were analysed using the Xpert BCD test. The primary outcomes were sensitivity, specificity, and a cost analysis for the Xpert BCD test in comparison to standard diagnostic methods such as urine cytology (UC) and white-light cystoscopy (WLC).</div></div><div><h3>Key findings and limitations</h3><div>The Xpert BCD test exhibited superior sensitivity to UC, particularly in identifying high-grade tumours. Importantly, Xpert BCD implementation has the potential to significantly reduce the number of unnecessary WLC procedures and streamline diagnostic pathways. The cost analysis also highlighted potential cost savings for Xpert BCD adoption in the ED setting.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our findings underscore the promise of Xpert BCD for revolutionising the diagnostic approach to BC in the ED for patients with gross haematuria. Its greater sensitivity and efficiency mean that Xpert BCD has the potential to improve patient care, optimise resource use, and alleviate the economic burden associated with unnecessary procedures.</div></div><div><h3>Patient summary</h3><div>Xpert Bladder Cancer Detection is a simple urine test that detects the presence of five genes associated with bladder cancer. We found that for patients visiting the emergency department because of blood in their urine, use of this test could save time and money over urine cell analysis (UCA) for ruling out or diagnosing bladder cancer. The test was also more sensitive in detecting higher-grade cancers. More research is needed to confirm our results.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 172-179"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base","authors":"Luke L. Wang ,&nbsp;Dhruv Puri ,&nbsp;Cesare Saitta ,&nbsp;Franklin Liu ,&nbsp;Jonathan A. Afari ,&nbsp;Margaret F. Meagher ,&nbsp;Kevin Hakimi ,&nbsp;Mimi V. Nguyen ,&nbsp;Aastha Shah ,&nbsp;Saeed Ghassemzadeh ,&nbsp;James D. Murphy ,&nbsp;Juan Javier-Desloges ,&nbsp;Rana R. McKay ,&nbsp;Ithaar H. Derweesh","doi":"10.1016/j.euros.2024.10.002","DOIUrl":"10.1016/j.euros.2024.10.002","url":null,"abstract":"<div><h3>Background and objective</h3><div>Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.</div></div><div><h3>Methods</h3><div>Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC. Trend analyses were conducted using the Cochran-Armitage test. Multivariable analyses were used to assess factors associated with sRCC diagnosis and clinicopathologic characteristics associated with all-cause mortality (ACM). Overall survival (OS) was computed via Kaplan-Meier analysis.</div></div><div><h3>Key findings and limitations</h3><div>sRCC incidence increased from 3.9% in 2010 to 4.1% in 2019 (<em>p</em> = 0.020). The incidence of stage I sRCC increased from 14.5% in 2010 to 19.2% in 2019 (<em>p</em> &lt; 0.001). sRCC diagnosis was associated with male sex, tumor size, cN1 status, and collecting duct histology. Worse ACM in localized sRCC was associated with age, tumor size, cN1 stage, collecting duct histology, and positive surgical margins; and was inversely associated with partial nephrectomy (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.49–0.76; <em>p</em> &lt; 0.001). Worse ACM in metastatic sRCC was associated with age, tumor size, cN1, collecting duct histology, positive surgical margins, and no surgery at the primary site (HR 1.66, 95% CI 1.20–2.30; <em>p</em> = 0.006). The 5-yr OS rates for stage I, stage II, stage III, and stage IV sRCC were 74%, 63%, 42%, and 16%, respectively (<em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions and clinical implications</h3><div>The proportion of sRCC cases overall and of stage I sRCC cases increased from 2010 to 2019, supporting the hypothesis of stage migration and the potential for early sarcomatoid dedifferentiation. Further studies on the causal mechanisms underpinning better survival after partial nephrectomy in localized disease and after cytoreductive surgery in metastatic disease are warranted.</div></div><div><h3>Patient summary</h3><div>We analyzed trends and outcomes for a type of aggressive kidney cancer (sarcomatoid renal cell carcinoma, sRCC) using records from the National Cancer Data Base. We found that the percentage of sRCC cases among all kidney cancers increased from 2010 to 2019. Factors such as tumor size and patient age were linked to worse survival. Surgery to remove the cancer was linked to better survival.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 96-105"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}